finance.yahoo.com ·
evolus eols q2 2025 earnings 203449546
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedEvolus, a medical aesthetics company, reported weak Q2 2025 earnings due to declining U.S. toxin market volumes. Jeuveau (botulinum toxin) sales fell for the first time. The company revised 2025 guidance down but maintains a long-term target. Impact is company-specific and U.S.-focused, with potential rebound in H2 2025. No direct commodity or supply chain scarcity; channel is demand_spike (negative) for aesthetic procedures.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Evolus Q2 2025 earnings below expectations.
- Jeuveau experienced first year-over-year decrease since launch.
- U.S. toxin market procedural volumes declined for three consecutive quarters.
- 2025 revenue guidance revised to $295M-$305M (11%-15% growth over 2024).
- Long-term goal of $700M by 2028 maintained.
Evolus's weak earnings indicate a 3-6% revenue decline for Jeuveau in the short term; consumer discretionary spending is pressured. Key risk: the decline may be due to competitive dynamics rather than broader demand.
Sign in to see all sector verdicts, full thesis and counter-argument debate.